BioXcel Therapeutics (BTAI) Misses Q1 EPS by 22c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q1 EPS of ($1.84), $0.22 worse than the analyst estimate of ($1.62). Revenue for the quarter came in at $210 thousand versus the consensus estimate of $447.1 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand
• S&P 500 may pull back before midterms, but Citi says buy the dip